CFS
MCID: CHR066
MIFTS: 61

Chronic Fatigue Syndrome (CFS)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome 12 74 54 42 3 15 17 71
Myalgic Encephalomyelitis 12 74 3
Postviral Fatigue Syndrome 12 32
Cfs 12 15
Encephalomyelitis, Myalgic 74
Fatigue Syndrome, Chronic 43
Myalgic Encephalitis 12
Chronic Fatigue 6

Classifications:



External Ids:

Disease Ontology 12 DOID:8544
ICD9CM 34 780.71
MeSH 43 D015673
NCIt 49 C3037
SNOMED-CT 67 52702003
ICD10 32 G93.3 R53.82
UMLS 71 C0015674

Summaries for Chronic Fatigue Syndrome

MedlinePlus : 42 What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome? The cause of CFS is unknown. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome? CFS symptoms can include Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome diagnosed? CFS can be difficult to diagnose. There is no specific test for CFS, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including Asking about your medical history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine or other tests What are the treatments for chronic fatigue syndrome? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary : Chronic Fatigue Syndrome, also known as myalgic encephalomyelitis, is related to depression and irritable bowel syndrome, and has symptoms including muscle weakness, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dinoprostone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

CDC : 3 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may get worse after people with the illness try to do as much as they want or need to do. This symptom is known as post-exertional malaise (PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.

Wikipedia : 74 Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a complex,... more...

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1082)
# Related Disease Score Top Affiliating Genes
1 depression 31.9 SLC6A4 MAOA HTR1A CRH
2 irritable bowel syndrome 31.8 TNF TLR4 SLC6A4 POMC IL6 IL1B
3 sleep disorder 31.4 TNF SLC6A4 POMC IL6 IL1B HTR1A
4 fibromyalgia 31.3 TNF SLC6A4 POMC IL6 IL1B IL10
5 personality disorder 31.2 SLC6A4 NR3C1 MAOA HTR1A CRH COMT
6 ige responsiveness, atopic 31.2 IL4 IL10 IFNG
7 dysthymic disorder 31.2 SLC6A4 MAOA HTR1A CRH
8 juvenile arthritis 31.1 IL6 IL10 CXCL8
9 generalized anxiety disorder 31.1 SLC6A4 NR3C1 MAOA HTR1A COMT
10 encephalitis 31.1 TNF IL6 IL4 IL1B IL10
11 allergic bronchopulmonary aspergillosis 31.1 IL4 IL10 IFNG
12 acute stress disorder 31.0 SLC6A4 POMC NR3C1 CRH
13 sexual disorder 31.0 SLC6A4 POMC HTR1A
14 alexithymia 31.0 SLC6A4 IL6 IL4 HTR1A COMT
15 lyme disease 31.0 TNF IL6 IL1B
16 neurotic disorder 31.0 TNF SLC6A4 MAOA IL6 HTR1A
17 hypochondriasis 30.9 SLC6A4 POMC HTR1A
18 interstitial cystitis 30.9 IL6 IL2 CXCL8
19 mood disorder 30.9 SLC6A4 POMC NR3C1 MAOA IL6 IL2
20 mental depression 30.9 TNF SLC6A4 POMC NR3C1 MAOA IL6
21 eating disorder 30.8 SLC6A4 POMC CRH COMT
22 sleep apnea 30.8 TNF SLC6A4 IL6 IL1B IL10 CXCL8
23 haemophilus influenzae 30.8 TNF CXCL8
24 severe combined immunodeficiency 30.8 IL6 IL4 IL2 IL10 IFNG
25 poliomyelitis 30.8 TNF IL4 IL10 IFNG
26 chronic active epstein-barr virus infection 30.7 IL2 IL10 IFNG
27 pharyngitis 30.7 TNF IL6 IL1B CXCL8
28 lung disease 30.7 TNF TLR4 IL6 IL4 IL1B IL1A
29 allergic rhinitis 30.7 NR3C1 IL4 IL10 IFNG CXCL8
30 restless legs syndrome 30.7 SLC6A4 POMC MAOA IL1B COMT
31 allergic hypersensitivity disease 30.7 TNF IL4 IL2 IL10 IFNG CXCL8
32 ileus 30.7 TNF POMC IL6 IL1B IL1A IL10
33 panic disorder 30.7 SLC6A4 POMC MAOA IL6 HTR1A CRH
34 anorexia nervosa 30.6 SLC6A4 POMC MAOA HTR1A CRH COMT
35 agoraphobia 30.6 SLC6A4 MAOA HTR1A CRH COMT
36 traumatic brain injury 30.6 IL6 IL10 COMT
37 thyroiditis 30.6 TNF IL6 IL4 IL2 IL10
38 attention deficit-hyperactivity disorder 30.6 SLC6A4 NR3C1 MAOA IL6 HTR1A COMT
39 herpes simplex 30.6 TNF RNASEL IL6 EIF2AK2
40 orchitis 30.6 TNF IL6 IL4 IL2 IL1B IL10
41 anxiety 30.5 TNF SLC6A4 POMC NR3C1 MAOA IL6
42 atypical depressive disorder 30.5 SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
43 myelitis 30.5 TNF IL6 IL10 CXCL8
44 psychotic disorder 30.5 SLC6A4 MAOA HTR1A COMT
45 pericarditis 30.5 TNF IL6 IL1B IFNG CXCL8
46 arthropathy 30.5 TNF IL6 IL1B IFNG
47 herpes zoster 30.5 TNF IL2 IL10 IFNG
48 juvenile rheumatoid arthritis 30.5 TNF IL6 IL2 IL1B IL10 IFNG
49 chickenpox 30.5 TNF IL6 IL4 IL2 IL10 IFNG
50 autoimmune disease 30.5 TNF IL6 IL4 IL2 IL1B IL1A

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:



Diseases related to Chronic Fatigue Syndrome

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:


muscle weakness, fatigue, fever, pruritus, myalgia, back pain, sciatica, muscle cramp, muscle rigidity, muscle spasticity, (non-specific) malaise and fatigue, other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CXCL8 IL10 IL1A IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CXCL8 EIF2AK2 IL10 IL1B IL2 TNF

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 COMT CRH HTR1A IFNG IL10 IL2
2 cardiovascular system MP:0005385 10.38 COMT HTR1A IFNG IL10 IL1A IL1B
3 homeostasis/metabolism MP:0005376 10.36 COMT CRH HTR1A IFNG IL10 IL1A
4 hematopoietic system MP:0005397 10.35 COMT CRH EIF2AK2 IFNG IL10 IL1A
5 cellular MP:0005384 10.34 CRH EIF2AK2 IFNG IL10 IL2 IL4
6 immune system MP:0005387 10.31 COMT CRH EIF2AK2 IFNG IL10 IL1A
7 endocrine/exocrine gland MP:0005379 10.27 COMT CRH IFNG IL10 IL2 IL4
8 integument MP:0010771 10.22 CRH IFNG IL10 IL1A IL1B IL4
9 digestive/alimentary MP:0005381 10.16 IFNG IL10 IL2 IL4 IL6 NR3C1
10 nervous system MP:0003631 10.13 COMT CRH HTR1A IFNG IL10 IL1B
11 liver/biliary system MP:0005370 10.07 CRH IFNG IL10 IL2 IL4 IL6
12 neoplasm MP:0002006 10.02 EIF2AK2 IFNG IL10 IL1A IL1B IL2
13 no phenotypic analysis MP:0003012 9.81 CRH HTR1A IFNG IL10 IL2 IL4
14 renal/urinary system MP:0005367 9.56 COMT CRH IFNG IL4 IL6 NR3C1
15 respiratory system MP:0005388 9.32 COMT CRH IFNG IL10 IL2 IL4

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dinoprostone Approved Phase 4 363-24-6 5280360
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Copper Approved, Investigational Phase 4 7440-50-8 27099
5
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
13
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
14
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
15
Ethanol Approved Phase 4 64-17-5 702
16
Sodium oxybate Approved Phase 4 502-85-2 5360545
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
19
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
22 Garlic Approved, Nutraceutical Phase 4 8008-99-9
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27 Tocotrienol Investigational Phase 4 6829-55-6
28 Calciferol Phase 4
29 Ginkgo Phase 4
30 Lemon Balm Phase 4
31 Diallyl Sulfide Phase 4
32 Allyl sulfide Phase 4
33 Hawthorn Phase 4
34 Copper Supplement Phase 4
35 Iron Supplement Phase 4
36 Tocopherols Phase 4
37 Tocotrienols Phase 4
38 Cyclooxygenase 2 Inhibitors Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Analgesics Phase 4
41 Antirheumatic Agents Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Anti-Infective Agents Phase 4
45 Central Nervous System Stimulants Phase 4
46 Phosphodiesterase Inhibitors Phase 4
47 Phosphodiesterase 5 Inhibitors Phase 4
48 Citrate Phase 4
49 Sildenafil Citrate Phase 4 171599-83-0
50 Contraceptive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 289)
# Name Status NCT ID Phase Drugs
1 The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
2 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation Unknown status NCT03542721 Phase 4 DA-5515;Placebo of DA-5515
5 High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study Unknown status NCT01926132 Phase 4 ascorbic acid 10g/20ml;Normal Saline 150ml
6 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
7 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
8 Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention Completed NCT00860236 Phase 4
9 Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome. Completed NCT00598585 Phase 4 Sildenafil (Viagra);Placebo
10 Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate Completed NCT02055898 Phase 4 Sodium Oxybate
11 Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study Completed NCT01071044 Phase 4 Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
12 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
13 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
14 A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis Completed NCT01165307 Phase 4 Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills;Naproxen sodium pills
15 Thiamin Against Robust IBD Fatigue Active, not recruiting NCT03634735 Phase 4 Thiamine
16 Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection. Not yet recruiting NCT04308278 Phase 4 2LEBV® / 2LXFS®;Placebo
17 IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial Not yet recruiting NCT04313972 Phase 4 low-dose naltrexone;Placebo oral tablet
18 Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome. Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
19 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Terminated NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
20 B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment. Unknown status NCT02229942 Phase 3 Rituximab;Placebo
21 Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome. Unknown status NCT01907711 Phase 2, Phase 3
22 Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects Unknown status NCT02041455 Phase 2, Phase 3 Melatonin and Placebo;Amitriptyline and Placebo;Melatonin and Amitriptylin
23 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: a Randomized Phase III Trial Unknown status NCT00658034 Phase 3
24 B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study. Completed NCT00848692 Phase 2, Phase 3 Rituximab;Saline (NaCl 0,9 %) (placebo)
25 A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) Completed NCT00215800 Phase 3 Ampligen
26 A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome Completed NCT00375973 Phase 2, Phase 3 Duloxetine;Placebo
27 Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue Completed NCT01742013 Phase 3 GCJBP Laennec Inj.;Placebo
28 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
29 A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS. Completed NCT02063126 Phase 2, Phase 3
30 Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+ Completed NCT00552682 Phase 3 Duloxetine 60 mg, QD
31 Efficacy of High Dose Vitamin C Parenteral Supplement on Amelioration of Fatigue in Company Workers After Work: A Double-Blind, Randomized Controlled Trial Completed NCT00633581 Phase 2, Phase 3
32 CSP#470 - A Randomized, Multi-Center, Controlled Trial of Multi-Modal Therapy in Veterans With Gulf War Illnesses Completed NCT00007748 Phase 3
33 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
34 A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis Completed NCT01149525 Phase 3 L-Carnitine;Placebo
35 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
36 The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. Completed NCT02315872 Phase 3 ACTH;Placebo
37 Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease Completed NCT00000571 Phase 3
38 A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1) Completed NCT01340872 Phase 3 ST10-021;Placebo Comparator
39 A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2) Completed NCT01352221 Phase 3 ST10;Placebo oral capsule
40 Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors Completed NCT01281904 Phase 2, Phase 3
41 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial Completed NCT00200096 Phase 3
42 Phase 3 Study of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis Completed NCT01631032 Phase 3 Qi-tonifying Chinese herbal products
43 CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications Completed NCT00007501 Phase 3
44 Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome Recruiting NCT03463915 Phase 3 Bladder instillation WITH triamcinolone acetonide;Bladder instillation WITHOUT triamcinolone acetonide
45 A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness Active, not recruiting NCT02865460 Phase 3 Ubiquinol;Placebo
46 The Exercise Response to Pharmacologic Cholinergic Stimulation in Preload Failure Enrolling by invitation NCT03674541 Phase 3 Pyridostigmine
47 Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Terminated NCT00518869 Phase 2, Phase 3 PG2
48 A 12-month Prospective, Phase IIIb, Multicenter, Open-label Clinical Trial to Assess Health-related Quality of Life (HRQoL) in Patients With Chronic or High-frequency Episodic Migraine Treated With Erenumab Who Present Associated Comorbidities Withdrawn NCT04114630 Phase 3 erenumab 70mg/mL
49 H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis Withdrawn NCT02548117 Phase 3 Finasteride
50 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months Unknown status NCT02444091 Phase 2 Cyclophosphamide

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


coenzyme Q10
Fish Oils
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

MalaCards organs/tissues related to Chronic Fatigue Syndrome:

40
Testes, Brain, Heart, Pituitary, Breast, Prostate, B Cells

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 5722)
# Title Authors PMID Year
1
Chronic fatigue syndrome: What nurses need to know. 42 61
32195878 2020
2
Treating medically unexplained symptoms via improving access to psychological therapy (IAPT): major limitations identified. 61 42
32020880 2020
3
Understanding neuromuscular disorders in chronic fatigue syndrome. 61 42
31814961 2019
4
Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. 54 61
18573538 2009
5
Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. 54 61
17803834 2008
6
Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. 54 61
18396793 2008
7
[Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome]. 54 61
17546343 2007
8
Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. 54 61
16740143 2007
9
Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. 54 61
17300722 2007
10
Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. 54 61
16277015 2005
11
2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. 54 61
15924878 2005
12
Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. 61 54
15691524 2005
13
Variability of the RNase L isoform ratio (37 kiloDaltons/83 kiloDaltons) in diagnosis of chronic fatigue syndrome. 61 54
15699437 2005
14
Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. 54 61
15710856 2005
15
Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders? 54 61
15922114 2005
16
Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. 61 54
15885924 2005
17
Reduction of serotonin transporters of patients with chronic fatigue syndrome. 54 61
15570154 2004
18
Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. 61 54
15110921 2004
19
RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. 61 54
12626460 2003
20
Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. 61 54
12118002 2002
21
Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. 61 54
11698994 2001
22
Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. 54 61
11502777 2001
23
Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. 61 54
11288761 2001
24
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. 61 54
11087963 2001
25
A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. 54 61
11104854 2000
26
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. 61 54
11030484 2000
27
A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. 54 61
11126321 2000
28
Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. 61 54
10356627 1999
29
Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. 54 61
9669518 1998
30
The low dose ACTH test in chronic fatigue syndrome and in health. 61 54
9713562 1998
31
A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. 61 54
9576011 1998
32
Fibromyalgia, chronic fatigue syndrome, and myofascial pain. 54 61
9567202 1998
33
Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. 54 61
9243369 1997
34
Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. 54 61
9046989 1997
35
Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. 54 61
7893988 1994
36
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. 61 54
8148461 1994
37
Patients' experiences and effects of non-pharmacological treatment for myalgic encephalomyelitis/chronic fatigue syndrome - a scoping mixed methods review. 61
32432991 2020
38
Mitochondria and immunity in chronic fatigue syndrome. 61
32470498 2020
39
Brain Responses in CFS and TMD to Autonomic Challenges: An Exploratory fMRI Study. 61
31461628 2020
40
Breathing pattern disorders (dysfunctional breathing) characteristics and outcomes of children and young people attending a secondary care respiratory clinic. 61
32449843 2020
41
Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. 61
32450550 2020
42
Research update: The relation between ME/CFS disease burden and research funding in the USA. 61
32568148 2020
43
Graded exercise therapy doesn't restore the ability to work in ME/CFS. Rethinking of a Cochrane review. 61
32568149 2020
44
Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS. 61
32568152 2020
45
Attentional processing and interpretative bias in functional neurological disorder. 61
32541544 2020
46
A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors. 61
32247028 2020
47
Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study. 61
31970624 2020
48
The concept of 'illness without disease' impedes understanding of chronic fatigue syndrome: a response to Sharpe and Greco. 61
32482748 2020
49
Epidemiological and clinical factors associated with post-exertional malaise severity in patients with myalgic encephalomyelitis/chronic fatigue syndrome. 61
32571354 2020
50
Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments. 61
32556004 2020

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-CO3 NC_012920.1:m.9355A>TSNV Uncertain significance 523307 rs1556423663 MT:9355-9355 MT:9355-9355

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 TNF TLR4 RNASEL POMC MAOA IL6
2
Show member pathways
13.8 TNF TLR4 NR3C1 IL6 IL4 IL2
3
Show member pathways
13.66 TNF IL6 IL4 IL2 IL1B IL1A
4
Show member pathways
13.53 TNF TLR4 IL6 IL4 IL2 IL1B
5
Show member pathways
13.43 TNF RNASEL POMC MAOA IL6 IL4
6
Show member pathways
13.42 TNF IL6 IL4 IL2 IL1B IL1A
7
Show member pathways
13.33 TNF TLR4 NR3C1 IL4 IL2 IL1B
8
Show member pathways
13.22 TNF TLR4 RNASEL IL6 IL2 IL1B
9
Show member pathways
13.08 TNF TLR4 IL6 IL4 IL2 EIF2AK2
10
Show member pathways
13.04 TNF TLR4 IL6 IL1B EIF2AK2 CXCL8
11
Show member pathways
13.02 TNF IL6 IL4 IL2 IL1B IL1A
12
Show member pathways
12.96 TNF TLR4 RNASEL IL6 IL2 IL1B
13 12.92 TNF RNASEL IL6 IL1B IFNG EIF2AK2
14
Show member pathways
12.87 TNF TLR4 IL6 IL2 IL1B IL1A
15
Show member pathways
12.85 TNF TLR4 IL6 IL1B IL1A CXCL8
16
Show member pathways
12.78 TNF TLR4 IL6 IL4 IL2 IL1B
17
Show member pathways
12.77 TNF TLR4 IL6 IL4 IL2 IL1B
18
Show member pathways
12.76 TNF IL1B IL1A IFNG EIF2AK2
19
Show member pathways
12.76 TNF IL6 IL2 IL1B IL10 IFNG
20
Show member pathways
12.73 TNF IL4 IL2 IL10 IFNG
21 12.73 TNF RNASEL IL4 IL2 IL1B IL10
22
Show member pathways
12.56 IL6 IL4 IL2 IL10 IFNG
23
Show member pathways
12.51 TNF IL6 IL4 IL1B IFNG CXCL8
24
Show member pathways
12.51 TNF IL6 IL4 IL2 IL1B IFNG
25
Show member pathways
12.5 TNF TLR4 IL6 IL1B IL1A IFNG
26
Show member pathways
12.47 TNF IL6 IL2 IL10 CXCL8
27 12.46 TNF TLR4 IL1B CXCL8
28
Show member pathways
12.46 TNF TLR4 IL4 IL1B IL1A IL10
29 12.45 TNF TLR4 IL6 IL1B CXCL8
30 12.42 TNF TLR4 IL6 IL1B IL1A IL10
31 12.41 TNF TLR4 IL6 IL1B CXCL8
32
Show member pathways
12.41 TNF TLR4 IL6 IL1A CXCL8
33 12.41 TNF TLR4 RNASEL IL6 IL1B CXCL8
34
Show member pathways
12.37 TNF TLR4 IL1B IL1A IFNG EIF2AK2
35
Show member pathways
12.37 TNF TLR4 IL6 IL4 IL1B IFNG
36
Show member pathways
12.36 TNF IL6 IL2 IL1B IL10
37
Show member pathways
12.34 TNF RNASEL IL6 IL4 IL2 IL1B
38 12.28 TNF TLR4 IL6 IFNG
39 12.21 TNF TLR4 IL6 IL2 IL1B IL10
40 12.2 TNF IL1B IL1A IFNG
41 12.19 TNF IL6 IL4 IL2 IL10 IFNG
42 12.16 TNF IL1B IL1A IFNG
43
Show member pathways
12.15 TLR4 IL2 IL1B IL1A
44 12.15 RNASEL IL6 IL1B IL1A IFNG CXCL8
45
Show member pathways
12.14 TNF TLR4 IL6 IL2 IL1B IL10
46
Show member pathways
12.1 IL4 IL2 IL1B IFNG
47 12.1 TNF IL6 IL1B IL1A CXCL8
48 12.1 TNF TLR4 IL6 IL1B IL10 IFNG
49 12.09 TNF IL6 IL4 IL1B IL1A
50 12.06 TNF TLR4 IL1B CXCL8

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF POMC IL6 IL4 IL2 IL1B
2 extracellular space GO:0005615 9.36 TNF POMC IL6 IL4 IL2 IL1B

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TLR4 POMC NR3C1 IL6 IL4 IL1B
2 positive regulation of cell proliferation GO:0008284 10.14 IL6 IL4 IL2 IL1B IFNG HTR1A
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF TLR4 RNASEL POMC NR3C1 IL6
4 negative regulation of cell proliferation GO:0008285 10.13 IL6 IL1B IL1A IL10 EIF2AK2 CXCL8
5 inflammatory response GO:0006954 10.08 TNF TLR4 IL6 IL1B IL1A CXCL8
6 defense response to virus GO:0051607 10.04 RNASEL IL6 IFNG EIF2AK2
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 TNF TLR4 IL1B IL1A
8 positive regulation of protein phosphorylation GO:0001934 10.03 TNF IL2 IL1B IFNG CRH
9 response to lipopolysaccharide GO:0032496 10.02 TLR4 IL1B IL10 COMT
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 IL6 IL1B EIF2AK2
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.98 TNF IL6 IL1B IL10
12 regulation of insulin secretion GO:0050796 9.92 TNF IL1B IFNG
13 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
14 humoral immune response GO:0006959 9.91 TNF IL6 IFNG
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR4 IL1B EIF2AK2
16 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL4 IL2 IL1B
17 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR4 IL2 IL1B IFNG
18 negative regulation of tumor necrosis factor production GO:0032720 9.9 TLR4 POMC IL10
19 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
20 negative regulation of viral genome replication GO:0045071 9.89 TNF RNASEL EIF2AK2
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF IL6 IL4 IL2 IFNG
22 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.88 TNF NR3C1 IL10
23 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 IL6 IL1B
24 positive regulation of B cell proliferation GO:0030890 9.87 TLR4 IL4 IL2
25 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B IL1A
26 negative regulation of interleukin-6 production GO:0032715 9.87 TNF TLR4 IL10
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.87 TNF TLR4 IL1B
28 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR4 IL2 IL1B
29 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL6 IL10
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF TLR4 IL1B IFNG
31 microglial cell activation GO:0001774 9.85 TNF IL4 IFNG
32 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR4 IL1B
33 positive regulation of vascular endothelial growth factor production GO:0010575 9.85 IL6 IL1B IL1A
34 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.85 IL4 IL2 IL1B IL1A
35 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
36 positive regulation of cytokine secretion GO:0050715 9.83 TNF IL1A IL10 IFNG
37 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TNF TLR4 IL6
38 positive regulation of glial cell proliferation GO:0060252 9.81 TNF IL6 IL1B
39 astrocyte activation GO:0048143 9.81 TNF IL1B IFNG
40 positive regulation of gene expression GO:0010628 9.81 TNF TLR4 SLC6A4 IL6 IL4 IL1B
41 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.8 TNF IL1B IFNG
42 cellular response to lipopolysaccharide GO:0071222 9.8 TNF TLR4 IL6 IL1B IL1A IL10
43 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 TNF IL1B IL10
44 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF TLR4 IL1B IL1A IFNG
45 positive regulation of neuroinflammatory response GO:0150078 9.76 TNF IL6 IL1B
46 positive regulation of chemokine production GO:0032722 9.76 TNF TLR4 IL6 EIF2AK2
47 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
48 response to molecule of bacterial origin GO:0002237 9.75 IL10 CXCL8
49 negative regulation of amyloid-beta clearance GO:1900222 9.75 TNF IFNG
50 positive regulation of isotype switching to IgG isotypes GO:0048304 9.75 IL4 IL2

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TNF TLR4 SLC6A4 RNASEL NR3C1 MAOA
2 cytokine activity GO:0005125 9.28 TNF IL6 IL4 IL2 IL1B IL1A
3 growth factor activity GO:0008083 9.26 IL6 IL4 IL2 IL10

Sources for Chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....